{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-006222","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.329558+00:00","generated_at":"2026-06-15T04:05:20.606975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug","bullets":["Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.","Cash and equivalents $7.47M; working capital $6.56M; raised $0.60M via ATM after quarter end.","FDA agreed on primary endpoint for pivotal Phase 3 study of EB05 (paridiprubart) in ARDS patients.","Canadian regulators authorized Phase 2 study of EB06 for vitiligo; Phase 2b topline results for EB01 in ACD reported.","Plans to file IND for Phase 2 study of EB07 in systemic sclerosis (scleroderma)."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-006222","json":"https://secwatch.observer/filing/0001654954-23-006222.json","markdown":"https://secwatch.observer/filing/0001654954-23-006222.md","text":"https://secwatch.observer/filing/0001654954-23-006222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:05:20.606975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8efbebc6fe61c6be7d217d15bfe6a2f7308d2932","claim":"Edesa Biotech, Inc. reported six months ended March 31, 2023 results: net income net loss of $4.67 million, EPS $0.24 per common share.","evidence_excerpt":"For the six months ended March 31, 2023, Edesa reported a net loss of $4.67 million, or $0.24 per common share, compared to a net loss of $8.95 million, or $0.66 per common share, for the six months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended March 31, 2023"},{"label":"Net income","value":"net loss of $4.67 million"},{"label":"EPS","value":"$0.24 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a47db367cefdd88ba2bff8761cb9d7d5f31ed875","claim":"Edesa Biotech, Inc. reported quarter ended March 31, 2023 results: net income net loss of $2.33 million, EPS $0.12 per common share.","evidence_excerpt":"For the quarter ended March 31, 2023, Edesa reported a net loss of $2.33 million, or $0.12 per common share, compared to a net loss of $4.57 million, or $0.33 per common share, for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $2.33 million"},{"label":"EPS","value":"$0.12 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}